Towards a rational screening strategy for albuminuria: Results from the unreferred renal insufficiency trial

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Van der Tol, Arjan ^a   Van Biesen, Wim ^a   Verbeke, Francis ^a   De Groote, Guy ^b   Vermeiren, Frans ^c   Eeckhaut, Kathleen ^c   Vanholder, Raymond ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b BARC CRI Laboratories   (Belgium)

^c Adhesia   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

ADOLESCENT; ADULT; AGED; ALBUMINURIA; ARTICLE; BELGIUM; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INTERMETHOD COMPARISON; KIDNEY FAILURE; MACROALBUMINURIA; MALE; MEDICAL EXAMINATION; MICROALBUMINURIA; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; COHORT ANALYSIS; MASS SCREENING; METHODOLOGY; MIDDLE AGED;

ADULT; ALBUMINURIA; COHORT STUDIES; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; RENAL INSUFFICIENCY;

EID: 78149438448     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013328     Document Type: Article

References (43)

1. Kramer A, Stel V, Zoccali C, Heaf J, Ansell D, et al. (2009) An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006. Nephrol Dial Transplant 24: 3557-3566.
2. ERA-EDTA Registry: ERA-EDTA Registry 2007 Annual report. Academic Medical Center, Amsterdam, the Netherlands, june 2009.
3. ERA-EDTA Registry: ERA-EDTA Registry 1998 Annual Report. Academic Medical Center, Amsterdam, The Netherlands, May 2003.
4. The concise 2009 Annual Data Report Atlas of Chronic Kidney Disease & End- Stage Renal Disease in the United States.
5. Bigazzi R, Bianchi S, Baldari D, Campese VM (1998) Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. Journal of Hypertension 16: 1325-1333.
6. Mogensen CE (1999) Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia 42: 263-285.
7. (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355: 253-259.
8. Keane WF, Zhang Z, Lyle PA, Cooper ME, de Zeeuw D, et al. (2006) Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol 1: 761-767.
9. van der Velde M, Halbesma N, de Charro FT, Bakker SJL, de Zeeuw D, et al. (2009) Screening for Albuminuria Identifies Individuals at Increased Renal Risk. Journal of the American Society of Nephrology 20: 852-862.
10. Hallan SI, Dahl K, Oien CM, Grootendorst DC, Aasberg A, et al. (2006) Screening strategies for chronic kidney disease in the general population: followup of cross sectional health survey. British Medical Journal 333: 1047-1050.
11. Fried L (2009) Are we ready to screen the general population for microalbuminuria? J Am Soc Nephrol 20: 686-688.
12. Romundstad S, Holmen J, Kvenild K, Aakervik O, Hallan H (2003) Clinical relevance of microalbuminuria screening in self-reported non-diabetic/nonhypertensive persons identified in a large health screening - The Nord- Trondelag Health Study (HUNT), Norway. Clinical Nephrology 59: 241-251.
13. Wilson JM, Jungner YG (1968) [Principles and practice of mass screening for disease]. Bol Oficina Sanit Panam 65: 281-393.
14. WHO STEPS Surveillance, part 3. Training and Practical Guides, section 3: guide to physical Measurements.
15. Warram JH, Gearin G, Laffel L, Krolewski AS (1996) Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. Journal of the American Society of Nephrology 7: 930-937.
16. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, et al. (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247-254.
17. Genuth S, Alberti KGMM, Bennett P, Buse J, DeFronzo R, et al. (2003) Followup report on the diagnosis of diabetes mellitus. Diabetes Care 26: 3160-3167.
18. Hallan SI, Stevens P (2010) Screening for chronic kidney disease: which strategy? J Nephrol 23: 147-155.
19. Nielen MM, Schellevis FG, Verheij RA (2009) The usefulness of a free self-test for screening albuminuria in the general population: a cross-sectional survey. BMC Public Health 9: 381.
20. Klausen KP, Scharling H, Jensen JS (2006) Very low level of microalbuminuria is associated with increased risk of death in subjects with cardiovascular or cerebrovascular diseases. Journal of Internal Medicine 260: 231-237.
21. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, et al. (2004) Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110: 32-35.
22. Hillege HL, Fidler V, Diercks GFH, van Gilst WH, de Zeeuw D, et al. (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106: 1777-1782.
23. Hillege HL, Janssen WMT, Bak AAA, Diercks GFH, Grobbee DE, et al. (2001) Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. Journal of Internal Medicine 249: 519-526.
24. Arnlov J, Evans JC, Meigs JB, Wang TJ, Fox CS, et al. (2005) Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 112: 969-975.
25. Metcalf PA, Scragg RK, Dryson E (1997) Associations between body morphology and microalbuminuria in healthy middle-aged European, Maori and Pacific Island New Zealanders. Int J Obes Relat Metab Disord 21: 203-210.
26. Klausen KP, Parving HH, Scharling H, Jensen JS (2007) The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality. Journal of Internal Medicine 262: 470-478.
27. Heathcote KL, Wilson MP, Quest DW, Wilson TW (2009) Prevalence and duration of exercise induced albuminuria in healthy people. Clin Invest Med 32: E261-265.
28. Weir MR, Bakris GL (2010) Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial? American Journal of Nephrology 31: 469-470.
29. Turnbull F (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362: 1527-1535.
30. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, et al. (2001) Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. Journal of the American Society of Nephrology: JASN 12: 218-225.
31. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD (1992) Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA: the journal of the American Medical Association 268: 3085-3091.
32. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359: 1577-1589.
33. Bohm M, Reil JC, Danchin N, Thoenes M, Bramlage P, et al. (2008) Association of heart rate with microalbuminuria in cardiovascular risk patients: data from ISEARCH. Journal of Hypertension 26: 18-25.
34. Inoue T, Iseki K, Iseki C, Ohya Y, Kinjo K, et al. (2009) Heart rate as a risk factor for developing chronic kidney disease: longitudinal analysis of a screened cohort. Clin Exp Nephrol 13: 487-493.
35. Facchini FS, Stoohs RA, Reaven GM (1996) Enhanced sympathetic nervous system activity. The linchpin between insulin resistance, hyperinsulinemia, and heart rate. Am J Hypertens 9: 1013-1017.
36. Gillman MW, Kannel WB, Belanger A, D'Agostino RB (1993) Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 125: 1148-1154.
37. Palatini P (2009) Elevated heart rate: a "new" cardiovascular risk factor? Progress in cardiovascular diseases 52: 1-5.
38. Jouven X, Empana JP, Escolano S, Buyck JF, Tafflet M, et al. (2009) Relation of heart rate at rest and long-term (.20 years) death rate in initially healthy middle-aged men. The American journal of cardiology 103: 279-283.
39. Ritz E, Ogata H, Orth SR (2000) Smoking: a factor promoting onset and progression of diabetic nephropathy. Diabetes Metab 26 Suppl 4: 54-63.
40. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, et al. (2004) Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292: 2227-2236.
41. (2002) K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. American Journal of Kidney Diseases 39: s1-s266.
42. Stehouwer CD, Fischer HR, Hackeng WH, den Ottolander GJ (1990) Identifying patients with incipient diabetic nephropathy. Should 24-hour urine collections be used? Arch Intern Med 150: 373-375.
43. Witte EC, Lambers Heerspink HJ, de Zeeuw D, Bakker SJ, de Jong PE, et al. (2009) First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol 20: 436-443.